Figure 7

Cellular uptake of both nanoparticles in different cell lines or with various pretreatment as detected through flow cytometry.
(A) Cellular uptake of unmodified and modified nanoparticles with FITC-labeled CD147 after incubation for 2 h; (B) HepG2 cell uptake of the two nanoparticles labeled with FITC after treatment for 4 h; (C) detailed HepG2 cell uptake rate of both nanoparticles for 2 and 24 h and the comparison of 2 h cell uptake between the over-expressed HepG2 cell line and the low-expressed HSC cell line; (D) competitive inhibitory effect of CD147 antibody on HepG2 cell uptake of α-Hed-CS-CD147-NPs with lactose on α-Hed-GC-NPs as positive control. *p < 0.05, **p < 0.01 versus control (nanoparticles only).